Abstract
Lung cancer is the second most common cancer in both men and women and thus a leading cause of cancer-related deaths worldwide. New efficient treatments especially for its advanced stages and metastases are desperately needed, particularly with regard to overcoming the resistance which thwarts the efficacy of most clinically established drugs such as the platinum complexes. Glimpses of hope are new metal-based drugs that have emerged over the past decade which displayed efficacy in patients with platinum-resistant tumors and metastases. This chapter provides an overview of the latest developments of such metal-based drugs against lung cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cooper S, Spiro SG (2006) Small cell lung cancer: treatment review. Respirology 11:241–248
Haura EB (2001) Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 8:326–336
Wong E, Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99:2451–2466
Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467–2498
Knauer S, Biersack B, Zoldakova M, Effenberger K, Milius W, Schobert R (2009) Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M. Anticancer Drugs 20:676–681
Ott I, Gust R (2006) Medizinische Chemie der Platinkomplexe. Pharm Unserer Zeit 35:124–133
Voigt W, Dietrich A, Schmoll H-J (2006) Cisplatin und seine Analoga. Pharm Unserer Zeit 35:134–143
Kodaira T, Nobukazu F, Tachibana H, Hidano S (2006) Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 26:2265–2268
Oshita F, Yamada K, Saito H, Noda K, Hamanaka N, Ikehara M (2004) Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. J Exp Ther Oncol 4:343–348
Gietema JA, Guchelaar H-J, de Vries EGE, Alenbacher P, Sleijfer DT, Mulder NH (1993) A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anticancer Drugs 4:51–55
Gietema JA, Veldhuis G-J, Guchelaar H-J, Willemse PHB, Uges DRA, Cats A, Boonstra H, van der Graaf WTA, Sleijfer DT, de Vries EGE, Mulder NH (1995) Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 71:1302–1307
Kavanagh JJ, Edwards CL, Freedman RS, Finnegan MB, Balat O, Tresukosol D, Bunk K, Loechner S, Hord M, Franklin JL, Kudelka AP (1995) A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol Oncol 58:106–109
Degardin M, Armand JP, Chevallier B, Cappeleare P, Lentz M-A, David M, Roche H (1995) A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. Invest New Drugs 13:253–255
Welink J, Boven E, Vermorken JB, Gall HE, van der Vijgh WJF (1999) Pharmacokinetics and pharmacodynamics of Lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal or liver function. Clin Cancer Res 5:2349–2358
Jones AL, Smith IE, Townsend HE, Rastogi RB (1991) Phase II study of a platinum complex CL 286558 zeniplatin in non small cell lung cancer NSCLC. Anti-Cancer Drug Des 6:363
Drees M, Dengler WM, Hendriks HR, Kelland LR, Fiebig HH (1995) Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. Eur J Cancer 31:356–361
Pendyala L, Cowens JW, Chheda G, Dutta SP, Creavne PJ (1988) Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. Cancer Res 48:3533–3536
Kramer B, Birch R, Greco A, Prestridge K, DeSimone P, Omura G (1988) Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer: a southeastern cancer study group trial. Am J Clin Oncol 11:643–645
Granfortuna J, Newman N, Ginsberg S, Louie A, Comis RL, Gullo JJ, Poiesz BJ (1989) Phase II study of iproplatin (CHIP) in previously treated small-cell lung cancer. Am J Clin Oncol 12:355–357
Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Schuster T, Keller G, Fend F, Peschel C (2010) Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102:500–505
Di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta E, Formento ML (1998) Cytotoxicity, cellular uptake and DNA binding of novel trinuclear platinum complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells. Anticancer Res 18:3113–3118
Kloster MBG, Hannis JC, Muddiman DC, Farrell N (1999) Conformation on the binding of a trinuclear platinum drug. Biochemistry 38:14731–14737
Scagliotti G, Novello S, Crino L, de Marinia F, Tonato M, Noberasco C, Selvaggi G, Massoni F, Gatti B, Camboni G (2003) Phase II trial of BBR3464, a novel bifunctional platinum analog, as second line treatment of non-small cell lung cancer patients. Lung Cancer 41:S223
Cmelak AJ, Choy H, Murphy BA, DeVore RF, Burkey B, Day TA, LaPorte KL, Johnson D (1999) Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer. Proc Am Soc Clin Oncol 18:392a
Choy H, Park C, Yao M (2008) Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 14:1633–1638
Chen Y, Guo Z, Parsons S, Sadler PJ (1998) Stereospecific and kinetic control over the hydrolysis of a sterically hindered platinum picoline anticancer complex. Chem Eur J 4:672–676
Holford J, Sharp S, Murrer B, Abrams M, Kelland L (1998) In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77:366–373
Sava G, Capozzi I, Clerici K, Gagliardi G, Alessio E, Mestroni G (1998) Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis 16:371–379
Sava G, Bergamo A, Zorzet S, Gava B, Casarsa C, Cocchietto M, Furlani A, Scarcia V, Serli B, Iengo E, Alessio E, Mestroni G (2002) Influence of chemical stability on the activity of the antimetastasis ruthenium complex NAMI-A. Eur J Cancer 38:427–435
Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, Sava G (1999) In vitro cell cycle arrest, in vivo action of solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther 289:559–564
Vacca A, Bruno M, Boccarelli A, Coluccia M, Ribatti D, Bergamo A, Garbisa S, Sartor L, Sava GL (2002) Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br J Cancer 86:993–998
Pintus G, Tadolini B, Posadino AM, Sanna B, Debidda M, Bennardini F, Sava G, Ventura C (2002) Inhibition of the MEK/ERK signalling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur J Biochem 269:5861–5870
Sava G, Frausin F, Cocchietto M, Vita F, Podda E, Spessotto P, Furlani A, Scarcia V, Zabucchi G (2004) Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. Eur J Cancer 40:1383–1396
Zorzet S, Bergamo A, Cocchietto M, Sorc A, Gava B, Alessio E, Iengo E, Sava G (2000) Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 295:927–933
Bergamo A, Gava B, Alessio E, Mestroni G, Serli B, Cocchietto M, Zorzet S, Sava G (2002) Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Int J Oncol 21:1331–1338
Velders AH, Bergamo A, Alessio E, Zangrando E, Haasnoot JG, Casarsa C, Cocchietto M, Zorzet S, Sava G (2004) Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmpt)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O) (dmso-S)(dmtp)] (dmpt = 5,7-Dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). J Med Chem 47:1110–1121
Allardyce CS, Dyson PJ, Ellis DJ, Heath SL (2001) [Ru(η 6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]-decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem Commun 15:1396–1397
Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G, Dyson PJ (2005) In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem 48:4161–4171
Guichard SM, Else R, Reid E, Zeitlin B, Aird R, Muir M, Dodds M, Fiebig H, Sadler PJ, Jodrell DI (2006) Anti-tumor activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds. Biochem Pharmacol 71:408–415
Biersack B, Zoldakova M, Effenberger K, Schobert R (2010) (Arene)Ru(II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cells. Eur J Med Chem 45:1972–1975
Yoneda T, Lyall RM, Alsina MM, Persons PE, Spada AP, Levitzki A, Zilberstein A, Mundy GR (1991) The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 51:4430–4435
Sawaya R (2004) Intracranial metastases: current management strategies. Blackwell Futura, Malden, xiv. 497
Magda D, Lepp C, Gerasimchuk N, Lee I, Sessler JL, Lin A, Biaglow JE, Miller RA (2001) Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxigen species. Int J Radiat Oncol Biol Phys 51:1025–1036
Hashemy SI, Ungerstedt JS, Avval FZ, Holmgren A (2006) Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281:10691–10697
Magda D, Lecane P, Miller RA, Lepp C, Miles D, Mesfin M, Biaglow JE, Ho VV, Chawannakul D, Nagpal S, Karaman MW, Hacia JG (2007) Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 65:3837–3845
Richards GM, Mehta MP (2006) Motexafin gadolinium (MGd) in the treatment of brain metastases. Expert Opin Pharmacother 8:351–359
Kovjazin R, Eldar T, Patya M, Vanichkin A, Lander HM, Novogrodsky A (2003) Ferrocene-induced lymphocyte activation and anti-tumor activity is mediated by redox-sensitive signalling. FASEB J 17:467–469
Mooney A, Corry AJ, Nà Ruairc C, Mahgoub T, O’Sullivan D, O’Donovan N, Crown J, Varughese S, Draper SM, Rai DK, Kenny PTM (2010) Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agents. Dalton Trans 39:8228–8239
Ornelas C (2011) Application of ferrocene and its derivatives in cancer research. New J Chem 35:1973–1985
Snegur LV, Nekrasov YS, Sergeeva NS, Zhilina ZV, Gumenyuk VV, Starikova ZA, Simenel AA, Morozova NB, Sviridova IK, Babin VN (2008) Ferrocenylalkyl azoles: bioactivity, synthesis, structure. Appl Organomet Chem 22:139–147
Simenel AA, Morozova EA, Snegur LV, Zykova SI, Kachala VV, Ostrovskaya LA, Bluchterova NV, Fomina MM (2009) Simple route to ferrocenylalkyl nucleobases. Antitumor activity in vivo. Appl Organomet Chem 23:219–224
Simenel AA, Dokuchaeva GA, Snegur LV, Rodionov AN, Ilyin MM, Zykova SI, Ostrovskaya LA, Bluchterova NV, Fomina MM, Rikova VA (2011) Ferrocene-modified thiopyrimidines: synthesis, enantiomeric resolution, antitumor activity. Appl Organomet Chem 25:70–75
Paik J, Vogel S, Piantedosi R, Sykes A, Blaner WS, Swisshelm K (2000) 9-cis-retinoids: biosynthesis of 9-cis-retinoic acid. Biochemistry 39:8073–8084
Wada A, Tode C, Hiraishi S, Tanaka Y, Ohfusa T (1995) Retinoids and related compounds; 18: a convenient synthesis of retinoic acid analogs having an anthraquinone ring. Synthesis 9:1107–1110
Barua AB, Olson JA (1985) Preparation of retinamides by use of retinoyl fluoride. J Lipid Res 26:258–262
Barua AB, Huselton CA, Olson JA (1996) Synthesis of novel glucuronide conjugates of retinoic carboxylic acids. Synth Commun 26:1355–1361
Nudelman A, Rephaeli A (2000) Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J Med Chem 43:2962–2966
Margaret CD, Curley J, Robert W, Kevin L, Tephly LA, Sikri V (2000) C-linked analogs of N-(4-hydroxyphenyl) retinamide. US/6117845
Long B, Liang S, Xin D, Yang Y, Xiang J (2009) Synthesis, characterization and in vitro antiproliferative activities of new 13-cis-retinoyl ferrocene derivatives. Eur J Med Chem 44:2572–2576
Jaouen G, Top S, Vessières A, Leclercq G, McGlinchey MJ (2004) The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. Curr Med Chem 11:2505–2517
Top S, Vessières A, Leclercq G, Quivy J, Tang J, Vaissermann J, Huché M, Jaouen G (2003) Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Chem Eur J 9:5223–5236
Ferreira AP, Ferreira da Silva JL, Duarte MT, Minas da Piedade MF, Robalo MP, Harjivan SG, Marzano C, Gandin V, Marques MM (2009) Synthesis and characterization of new organometallic benzo[b]thiophene derivatives with potential antitumor properties. Organometallics 28:5412–5423
McMorris TC, Anchel M (1963) The structures of the basidiomycete metabolites illudin S and illudin M. J Am Chem Soc 85:831–832
Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R (1996) Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14:161–167
Dowell JE, Johnson DH, Rogers JS, Shyr Y, McCullough N, Krozely P, DeVore RF (2001) A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell lung cancer previously treated with chemotherapy. Invest New Drugs 19:85–88
Knauer S, Biersack B, Zoldakova M, Effenberger K, Milius W, Schobert R (2009) Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M. Anticancer Drugs 20:676–681
Schobert R, Seibt S, Mahal K, Ahmad A, Biersack B, Effenberger-Neidnicht K, Padhye S, Sarkar FH, Mueller T (2011) Cancer selective metallocenedicarboxylates of the fungal cytotoxin illudin M. J Med Chem 54:6177–6182
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Biersack, B., Schobert, R. (2016). Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases. In: Ahmad, A., Gadgeel, S. (eds) Lung Cancer and Personalized Medicine. Advances in Experimental Medicine and Biology, vol 893. Springer, Cham. https://doi.org/10.1007/978-3-319-24223-1_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-24223-1_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-24221-7
Online ISBN: 978-3-319-24223-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)